Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Megan Tu"'
Autor:
Mark Clemons, Michelle Liu, Carol Stober, Gregory Pond, Mashari Jemaan Alzahrani, Michael Ong, Scott Ernst, Christopher Booth, Mihaela Mates, Anil Abraham Joy, Olexiy Aseyev, Phillip Blanchette, Lisa Vandermeer, Megan Tu, Kednapa Thavorn, Dean Fergusson
Publikováno v:
Journal of Bone Oncology, Vol 30, Iss , Pp 100388- (2021)
Background: We present the 2-year results of a randomised trial comparing 4- versus 12-weekly bone-targeting agents (BTAs) in patients with bone metastases from breast or castration-resistant prostate cancer (CRPC). Patients and Methods: Patients wit
Externí odkaz:
https://doaj.org/article/0fd5e17abcb54cc69eaa0bfff560e243
Publikováno v:
Health Research Policy and Systems, Vol 22, Iss 1, Pp 1-13 (2024)
Abstract Introduction Previous studies have explored facilitators and barriers to research conducted by allied health professionals in general medical settings. Since the mental health system is acknowledged to be significantly under-funded and more
Externí odkaz:
https://doaj.org/article/a3890522dcb54e759e53915f6c667c97
Autor:
Barbara Zangerl, Wilson Luu, Lisa Dillon, Megan Tu, Michael Kalloniatis, Angelica Ly, Emma Bartley
Publikováno v:
Clinical and Experimental Optometry. 103:733-741
Vision impairment can have a significant impact on the wellbeing and quality of life of an individual. Vision rehabilitation has the potential to improve these areas; however, four in five patients with vision impairment are not being referred to the
Autor:
Christopher M. Booth, Mashari Alzahrani, Lisa Vandermeer, Michelle Liu, Anil A. Joy, Michael Ong, Megan Tu, Mark Clemons, Carol Stober, REaCT investigators, Gregory R. Pond, Mihaela Mates, Olexiy Aseyev, Phillip S. Blanchette, Scott Ernst, Dean Fergusson, Kednapa Thavorn
Publikováno v:
Journal of Bone Oncology, Vol 30, Iss, Pp 100388-(2021)
Background We present the 2-year results of a randomised trial comparing 4- versus 12-weekly bone-targeting agents (BTAs) in patients with bone metastases from breast or castration-resistant prostate cancer (CRPC). Patients and Methods Patients with
Autor:
Terry L. Ng, Fred R. Hirsch, Paul Mitchell, Caicun Zhou, Kim Ellison, Kenichi Suda, Leslie Rozeboom, Christopher J. Rivard, Dexiang Gao, Shengxiang Ren, Yiwei Liu, Gareth Rivalland, Megan Tu, Charles Caldwell, Qinrui Tian, Hui Yu, Nadav Amar
Publikováno v:
Lung Cancer. 125:115-120
Herpes Virus Entry Mediator (HVEM) is an important immune checkpoint in cancer recognition. HVEM expressed on tumor cell membranes activates immune cell signaling pathways leading to either inhibition of activity (B- and T-lymphocyte attenuator, BTLA
Publikováno v:
Contemporary Clinical Trials Communications, Vol 37, Iss , Pp 101241- (2024)
The Critical Path Institute convened the Support Flexible Approaches to PRO Data Collection project as part of the eCOA: Getting Better Together Initiative which was instigated to identify and address common challenges and drive positive change with
Externí odkaz:
https://doaj.org/article/f51923251e3e47a38524d2a613c61d08
Autor:
Jesse J. Carlson, Megan Turner, Austin Katona, Sean Kelly, Timothy R. Sterling, Peter F. Rebeiro
Publikováno v:
Journal of Clinical and Translational Science, Vol 8, Pp 11-11 (2024)
OBJECTIVES/GOALS: The COVID-19 pandemic disrupted HIV care, though it prompted preventive measures for respiratory pathogens, particularly among PWH. We therefore quantified trends in respiratory ADE incidence during vs. before the COVID-19 pandemic
Externí odkaz:
https://doaj.org/article/c8d6de132d6a43d293f1d0b4ccf1c03b
Autor:
Megan Tucker
Publikováno v:
Phenomenology & Practice, Vol 18, Iss 1 (2023)
Our own animately e/motional bodies are yearning for relationships with other bodies of the more-than-human kind. To support this opinion, I describe an intra-action caring for three rescued piglets that led to an awareness of human animal and animal
Externí odkaz:
https://doaj.org/article/d20fb0565d5840c497ccdd648adbdad7
Autor:
Megan Tu, Emanuel F. Petricoin, James C. Costello, Hedvig Vekony, Annie Jean, Julia D. Wulfkuhle, Dan Theodorescu, Molishree Joshi, Andrew Goodspeed, Teemu D. Laajala, Robert T. Jones, Tahlita C.M. Zuiverloon, Colin Sempeck
Publikováno v:
Cancer Research. 80:4091-4091
Gemcitabine and cisplatin (GC) combination neoadjuvant chemotherapy (NAC) is standard of care for patients with muscle-invasive bladder cancer (MIBC). This combination is preferred due to its favorable toxicity profile. Approximately 25% of NAC treat
Autor:
Robert T. Jones, Hedvig Vekony, Colin Sempeck, Megan Tu, Tahlita C.M. Zuiverloon, Emanuel F. Petricoin, Teemu D. Laajala, Annie Jean, Molishree Joshi, James C. Costello, Julia D. Wulfkuhle, Dan Theodorescu, Andrew Goodspeed
Publikováno v:
Clinical Cancer Research. 26:B11-B11
Neoadjuvant platinum-based chemotherapy (NAC) followed by radical cystectomy is the preferred first-line option for treating patients diagnosed with muscle-invasive bladder cancer (MIBC). One of the two most commonly utilized chemotherapy regimens fo